Previous 10 | Next 10 |
CytoSorbents Announces Health Canada Regulatory Approval For Pivotal STAR-T Trial PR Newswire PRINCETON, N.J. , Jan. 23, 2023 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensiv...
CytoSorbents Appoints Irina B. Kulinets, PhD, as Senior Vice President of Global Regulatory Affairs PR Newswire Dr. Irina Kulinets , seasoned U.S. and international medical device regulatory expert, joins CytoSorbents' executive management team to lead FDA marketing approv...
Healthcare company CytoSorbents ( NASDAQ: CTSO ) rose ~7% after the announcement that it received $5M in non-dilutive debt financing under an existing loan facility. The amended and restated loan and security agreement with Bridge Bank, which provided for a term loan commitme...
Medical device maker Cytosorbents Corporation ( NASDAQ: CTSO ) announced Thursday that California-based Bridge Bank provided the company with $5M debt financing, and the two parties agreed to extend a loan agreement. $5M debt financing is part of a term loan commitment of up to $15M t...
CytoSorbents Receives $5M in Non-Dilutive Debt Financing from Bridge Bank and Extends Loan Agreement PR Newswire Non-dilutive debt capital at market favorable terms strengthens the balance sheet and provides additional working capital to fund key clinical and commercial initia...
A New Jersey-based healthcare company captured the attention of the trading community on Wednesday after it was announced that it has received the recommendation from the independent Data and Safety Monitoring Board ( %DSMB ) to continue the pivotal Safe and Timely Antithrombotic Removal ...
CytoSorbents ( NASDAQ: CTSO ) is trading ~4% higher premarket after it received the recommendation from the independent Data and Safety Monitoring Board to continue the Safe and Timely Antithrombotic Removal – Ticagrelor (STAR-T) trial as planned without any modificati...
CytoSorbents Receives Recommendation from Independent Data and Safety Monitoring Board to Continue Pivotal STAR-T Trial As Planned Without Modifications PR Newswire PRINCETON, N.J. , Dec. 21, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a...
CytoSorbents Announces Pivotal STAR-T Trial Reaches First Milestone With 40 Patients Enrolled PR Newswire PRINCETON, N.J. , Nov. 14 , 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening condi...
CytoSorbents Corporation (CTSO) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Michelle Almonte - Executive Assistant to CEO Phillip Chan - Chief Executive Officer Kathleen Bloch - Chief Financial Officer Christian Steiner -...
News, Short Squeeze, Breakout and More Instantly...
CytoSorbents Corporation Company Name:
CTSO Stock Symbol:
NASDAQ Market:
CytoSorbents Corporation Website:
PRINCETON, N.J., Aug. 01, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of deadly conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces that it has regained comp...
PRINCETON, N.J., July 29, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of deadly conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, is proud to announce the launch of ...
PRINCETON, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces it will present...